NCT07682870
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Start date changed from estimate of Sep 4, 2026 to Nov 11, 2026
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 10 words
- Primary endpoints: details revised at 1 of 2 entries
- Interventions: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection (Drug) to Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection (Drug)
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety:Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: 12 months
MTD/RP2D
Timeframe: During the 28 day DLT observation period
Secondary (8)
Level of deoxyribonucleic acid (DNA)
Interleukin level
ORR
Duration of relief(DOR)
DCR
Show 3 moreShow less
PFS
Immunogenicity Parameters
Efficacy and Safety of VG2025 and Its Correlation with CEA Levels
Arms and interventions
3+3 designExperimental
This is an open label, single-arm trial using standard 3+3 design, in up to 42 HSV seropositive subjects. This rule-based design proceeds with cohorts of three patients
Drugs: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
Sites
1 site in 1 country
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, China